HeartBeam (BEAT) Stock Forecast & Price Target

HeartBeam is attractive fundamentally because its patented 3D ECG platform and FDA-cleared solutions address large, underpenetrated markets in ambulatory cardiac monitoring and heart attack detection, while its on-demand 12-lead capability differentiates it from typical 1–3 lead MCT devices. Near-term execution risk is balanced by real commercialization progress, including flagship partnerships with ClearCardio and Atelier Health, a limited market release underway, and first-patient enrollment in the ALiGN-ACS pilot study, which could help validate broader adoption and future FDA pathways. Financially, the company posted no revenue and a $4.7M net loss in 1Q26, but raised $11.5M in April 2026 for pro forma cash of about $12.4M, supporting the ramp toward meaningful revenue in 2H26 and potential cash flow breakeven at roughly 30,000 patients in 2028.

HeartBeam is facing a highly uncertain transition away from its limited arrhythmia commercialization, with management redirecting scarce financial and human resources toward a myocardial infarction indication that still requires clinical validation, algorithm development, and a regulatory pathway. Although the company cites a $15B MI opportunity within a broader $40B platform and has encouraging pilot progress, it has no visibility into approval timing or revenue ramp-up, while 2Q26 showed a $5.0M net loss, ($3.3M) in operating cash flow, and just $8.7M in cash at June 2026. That weak liquidity profile, combined with likely capital needs within the next 12 months, dilution and going-concern risk, and only limited near-term revenue from the FDA-cleared arrhythmia product, supports a negative outlook.